Private equity activity in the pharmaceutical industry in France remained flat in 2023

In value terms, private equity deal activity in France increased by 8% in Q2 2023 compared with the previous quarter’s total of $101.1m and rose by 307% as compared to Q2 2022. Related deal volume remained flat in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.

The top-ranked financial advisors supporting these private equity deals in France in Q2 2023 were Clearwater International Ltd (France); Deloitte Conseil; Germain Maureau with 1, 1, 1 deals respectively.

The top-ranked legal advisorss supporting these private equity deals in France Q2 2023 were McDermott Will & Emery; CMS Legal Services EEIG; DLA Piper with 2, 1, 1 deals respectively.

For further understanding of GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.

This content was updated on 18 July 2023

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Deals Database tracks global deal activity, including mergers, acquisitions, capital raising, strategic alliances, and licensing agreements. Proprietary analysis is used to group deals into key thematic areas and granular sectors across the world’s largest industries.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Deal type includes Buyouts and Direct Investments done by Private Equity firms.

Scoop: CNS biotech MapLight Therapeutics eyes $175M raise for PhII clinical trials in schizophrenia, autism and Parkinson’s

MapLight Therapeutics, a biotech focused on central nervous system disorders, is eyeing a large $175 million financing as it beefs up the C-suite and advances

July 22, 2023

Florida CNS gene therapy biotech shuts down

Seven-year-old gene therapy startup Lacerta Therapeutics has folded and sold its assets, a board member confirmed to Endpoints News. The University of Florida spinout, based

August 6, 2024

Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says

Biogen on Wednesday said that an experimental, higher dose of its spinal muscular atrophy drug Spinraza met the primary endpoint of a clinical trial comparing

September 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.